Showing 8331-8340 of 10903 results for "".
Off-label Uses for Biologics
https://practicaldermatology.com/topics/psoriasis/off-label-uses-for-biologics/18964/Derm Insider Bonus Content: Host Neal Bhatia speaks with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD about various potential off-label uses for current and investigational systemic psoriasis therapies.The Importance of Planning
https://practicaldermatology.com/topics/practice-management/the-importance-of-planning/19082/Failing to plan is planning to fail, say Jay A. Shorr, BA, MBM-C, CAC I-V and Mara Shorr, BS, CAC II-V of The Best Medical Business Solutions. They tell aesthetic practices how to lay the foundation for success in minimally invasive procedures.The Noah Family
https://practicaldermatology.com/conferences/noah-worcester/the-noah-family/57061/Amy Spizuoco, DO, explains what makes the Noah Worcester Dermatological Society’s annual meetings special and what she took away from the 2026 Annual Meeting.Preparing for the Return of Measles
https://practicaldermatology.com/conferences/noah-worcester/preparing-for-the-return-of-measles/57064/Miriam Bettencourt, MD discusses her presentation, “Mission Impossible: The Spotted Reckoning,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.Tips for Treating Children
https://practicaldermatology.com/conferences/noah-worcester/tips-for-treating-children/57066/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, discusses her two Alfred L. Weiner lectures on pediatric dermatology from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.Dermwire TV: 2025 in Review
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-2025-in-review/54093/Dermwire TV takes a look back at the most popular stories from the Practical Dermatology news and multimedia ecosystem.Effector Cell Response Inhibitors
https://practicaldermatology.com/videos/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urJournal Club: Combination Therapy With Dupilumab and Upadacitinib
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combination-therapy-with-dupilumab-and-upadacitinib/32408/Neal Bhatia, MD, FAAD, and Ted Lain, MD, MBA, FAAD, discuss the International Journal of Dermatology article “Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis,” and their own experiences with similar treatment strategies.FDA Approval for Delgocitinib
https://practicaldermatology.com/videos/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.Addressing Equity Gaps in Psoriasis Research
https://practicaldermatology.com/videos/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.